SIRPA and renal carcinoma: A bsAb combining the variable domain of the CD70 antibody vorsetuzumab with the variable domain of SIRPα‐targeting antibody KWAR23 induced more macrophage‐mediated phagocytosis in four out of four renal carcinoma cell lines compared to treatment with SIRPα‐Fc.33